Please assess the completion status of the following clinical trial:

Trial Title: PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Diagnosis of OAB and associated symptoms of UUI and qualify with at least 3 episodes of mild, moderate, or severe urgency demonstrated on a 3-day urinary voiding diary~3. Experiencing UUI symptoms for at least 3 months~4. No prior treatment with anticholinergics/antimuscarinics or beta 3-agonists medications to treat OAB~5. Willing and able to accurately complete voiding diaries and questionnaires, attend visits, and comply with the study protocol~6. Willing and able to provide signed and dated informed consent~Exclusion Criteria:~1. Have received anticholinergics/antimuscarinics or beta 3-agonists medications to treat OAB or advanced therapy treatment options for OAB (botulinum toxin injections, sacral neuromodulation, or percutaneous tibial nerve stimulation/neuromodulation)~2. Primary stress incontinence or mixed incontinence where the stress component overrides the urge component~3. Have implantable pacemakers or implantable defibrillators~4. Use of transcutaneous electrical nerve stimulation (TENS) in pelvic region, back or legs~5. Women who are pregnant or planning to become pregnant during the course of the study~6. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol~7. Nerve damage that could impact either tibial nerve or pelvic floor function.~8. Subjects prone to excessive bleeding~9. Inadequate skin integrity in the area of PTNM needle placement~10. History of diabetes unless the diabetes is well-controlled through diet and/or medications~11. Have symptomatic urinary tract infection (UTI)~12. Participation in any research study involving or impacting gynecologic, urinary or renal function within the 4-week period prior to or plans to participate during study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NURO System PTNM Therapy (Type: OTHER): Subjects will undergo 12 PTNM therapy sessions, administered weekly, utilizing the NURO system.

Based on this trial design, predict the completion outcome and termination type (if applicable).